ECOR electroCore
WatchlistelectroCore News
Dr. Peter Staats to Host Analyst Day on the Science Behind GammaCore Non-Invasive Vagus Nerve Stimulation (NVNS) on Tuesday, November 21, 2023
ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's Chief Medical Officer, Dr. Peter
Analysts' Opinions Are Mixed on These Technology Stocks: Unity Software (U) and Electrocore (ECOR)
ElectroCore, Inc. (NASDAQ:ECOR) Q3 2023 Earnings Call Transcript
electroCore, Inc. (NASDAQ:ECOR) Q3 2023 Earnings Call Transcript November 8, 2023
HC Wainwright & Co. Maintains Buy on ElectroCore, Raises Price Target to $11
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains electroCore (NASDAQ:ECOR) with a Buy and raises the price target from $10 to $11.
ElectroCore Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/09/2023 90.64% HC Wainwright & Co. $10 → $11 Maintains Buy 08/10/2023 73.31% HC Wainwright & Co. → $10
Electrocore's Strong Financial Performance and Promising Growth Prospects: A Buy Rating Analysis
ElectroCore Inc (ECOR) Reports Substantial Sales Growth in Q3 2023
ElectroCore Sees FY23 Revenue $15M-$15.5M Vs $14.43M Est.
ElectroCore Sees FY23 Revenue $15M-$15.5M Vs $14.43M Est.
ElectroCore Q3 EPS $(0.68) Up From $(1.20) YoY, Sales $4.51M Up From $1.98M YoY
electroCore (NASDAQ:ECOR) reported quarterly losses of $(0.68) per share. This is a 43.33 percent increase over losses of $(1.20) per share from the same period last year. The company reported $4.51
ElectroCore GAAP EPS of -$0.68 Beats by $0.02, Revenue of $4.5M Beats by $0.72M
Earnings Flash (ECOR) ELECTROCORE Posts Q3 Revenue $4.5M, Vs. Street Est of $3.8M
04:04 PM EST, 11/08/2023 (MT Newswires) -- Earnings Flash (ECOR) ELECTROCORE Posts Q3 Revenue $4.5M, vs. Street Est of $3.8M
Earnings Scheduled For November 8, 2023
Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter. • Evotec (NASDAQ:EVO) is estimated to report quarterly loss at $0.05 per share on reve
ElectroCore Q3 2023 Earnings Preview
ElectroCore to Participate in Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum
ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger,
Data Highlighting Non-invasive Vagus Nerve Stimulation (NVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting
Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional DyspepsiaFIGURE 1Primary Endpoint (n=35): Average number of nausea
ElectroCore's GammaCore Therapy Will Continue To Be Listed In The U.K's National Health Service Supply Chain Catalogue For Additional Two Years Till March 17, 2026. The Listing Commenced On June 4, 2019, Was Scheduled To Terminate On March 18, 2024
ElectroCore's GammaCore Therapy Will Continue To Be Listed In The U.K's National Health Service Supply Chain Catalogue For Additional Two Years Till March 17, 2026. The Listing Commenced On June 4, 20
ElectroCore, Inc. Announces Data Highlighting Non-Invasive Vagus Nerve Stimulation For Treatment Of Acute Neurological Injury Presented At 2023 World Stroke Congress
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from two abstracts being presented at the 15th World Stroke Congress held October 10-12, 2023, in Toronto, Canada on the possible role of nVNS in the treatment of acute neurological injuries.
ElectroCore to Announce Third Quarter Financial Results on Wednesday, November 8
ROCKAWAY, N.J., Oct. 09, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third
ElectroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference
ROCKAWAY, N.J., Oct. 05, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger,
GammaCore Non-Invasive Vagus Nerve Stimulation (NVNS) Improves Attention and Working Memory in Patients With Post Traumatic Stress Disorder (PTSD)
ROCKAWAY, N.J., Sept. 27, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of two peer reviewed publications supporting the use of gammaCore (non-invasive vagal nerve stimulation; nVNS) in patients with posttraumatic stress disorder (PTSD).